Cosmetic composition of liquid crystal lipid particles for personal care applications

Abstract

The invention relates to liquid crystal lipid particles. The present invention relates to liquid crystal lipid particles for use in topical compositions having high moisturizing effect, excellent skin feel, skin softness and skin smoothness benefits.

Description

[0001] This application is a divisional application of a patent application with application number 202080011470.1, application date January 27, 2020, and invention name “Cosmetic composition of liquid crystal lipid particles for personal care applications”. Technical Field

[0002] The present invention relates to liquid crystal lipid particles. In particular, the present invention relates to liquid crystal lipid particles for use in topical compositions. Topical compositions containing liquid crystal lipid compositions have high moisturizing efficacy, excellent skin feel, skin softness and skin smoothness benefits. Background Art

[0003] The skin plays a very important role as a barrier membrane, which prevents any loss of essential biological components such as water, and also protects against any biological, chemical or physical invasion by external microorganisms, chemicals, ultraviolet rays, etc. The part that acts as a barrier membrane is the keratinocyte layer, or stratum corneum, which is about 20 μm thick and is located in the outermost layer of the skin. It forms a tough barrier membrane with a structure in which keratinocytes are stacked like bricks (bound to each other by intercellular lipids that act as mortar).

[0004] The stratum corneum has important barrier functions, the most important of which is to prevent excessive transepidermal water loss ("TEWL"). In addition to delaying TEWL, the thin sheets of lipid lamellar membrane also protect against the intrusion of foreign chemicals and microorganisms.

[0005] Lamellar liquid crystal-forming emulsifiers are marketed by cosmetic ingredient suppliers as mimicking the multilamellar lipid structure of the stratum corneum.

[0006] In the cosmetics sector, it is believed that smaller particles are more easily absorbed by the skin and can repair damage more easily and effectively. The purpose of incorporating nanotechnology into cosmeceuticals is to make perfumes smell longer, sunscreens protect the skin, anti-aging creams resist the years, and moisturizers retain moisture in the skin. Some of the innovations based on nanotechnology include nanoemulsions (which are transparent and have unique touch and texture properties), nanocapsules (used in skin care products), nanopigments (which are transparent and improve the efficacy of sunscreen products), liposomal formulations (they contain small vesicles composed of traditional cosmetic materials that protect oxygen or light-sensitive cosmetic ingredients), lipid vesicles (niosomes), nanocrystals, solid lipid nanoparticles, carbon nanotubes, fullerenes, and dendrimers. The main advantages of using nanoparticles in cosmeceuticals include improving the stability of cosmetic ingredients (such as vitamins, unsaturated fatty acids, and antioxidants) by encapsulating them in nanoparticles; effectively protecting the skin from harmful ultraviolet (UV) rays; aesthetically pleasing products (for example, in mineral sunscreens, the use of smaller active mineral particles allows them to not leave a noticeable white cast when applied); targeting active ingredients to the desired site and controlling the release of active ingredients to prolong the effect.

[0007] WO 2005 / 108383 A1 discloses an oil-in-water emulsion comprising a mixture of at least two sucrose esters and at least one solid fatty alcohol, the mixture forming a multi-layer liquid crystal network that effectively moisturizes and protects the skin and provides a useful carrier for delivering active ingredients. US 2009 / 0239956 A1 relates to a lamellar liquid crystal composition for cosmetic use, which comprises one or more polyglycerol monoethers each having a specific structure, and is used for makeup removal and cosmetics containing the cosmetic composition.

[0008] US 2009 / 0239956 A1 relates to a lamellar liquid crystal composition for cosmetic use, which comprises one or more polyglycerol monoethers each having a specific structure, and is used for makeup removal and cosmetics containing the same.

[0009] US 2012 / 0282357 A1 discloses a method for regulating the calcium ion content in the epidermis, comprising applying a material for enhancing the skin barrier function to the skin of a subject, wherein the material is selected from the group consisting of: anise extract, starfish extract, L-carnitine, royal jelly hydrolysate α, ε-bis(γ-N-lauroylglutamyl)lysine, palm extract, ε, γ-glutamyllysine, Coptis chinensis extract and Citrus aurantium peel extract.

[0010] WO 2016 / 003118 A1 relates to a multiphase cosmetic composition comprising cholesteric liquid crystals, resulting in an improved feeling during use.

[0011] Although efforts have been made to enhance the skin barrier function by using various approaches such as natural extracts formulated in skin creams, lotions, etc., which are biologically effective in enhancing the skin barrier function, they have not resulted in an enhancement of the physical barrier function.

[0012] Therefore, there is still a need to effectively improve skin barrier function by enhancing the skin's own ability to maintain and / or repair its barrier strength, thereby forming a completely natural protective barrier. In addition, there is also a need for skin compositions that exhibit enhanced skin protective properties and enhanced skin moisturizing effects. Summary of the invention

[0013] Surprisingly, the liquid crystal lipid particles of the present invention were found to be effective in improving the barrier function and protecting the skin from harmful pollutants, and also enhance the skin moisturizing effect.

[0014] Liquid crystal lipid particles are another type of system that offers the advantages of both liquid and solid phases. These particles can be easily fabricated and offer several advantages.

[0015] Therefore, in one aspect, the present invention relates to a method for reducing dust adhesion to the skin, comprising applying to the skin at least one liquid crystal lipid particle. The liquid crystal lipid particle comprises a compound represented by general formula (I) to (VI), comprising,

[0016] At least one compound of formula (I)

[0017]

[0018] wherein m is an integer in the range of ≥10 to ≤24 and n is an integer in the range of ≥1 to ≤25, at least one compound of formula (II),

[0019]

[0020] wherein a is an integer in the range of ≥10 to ≤24,

[0021] At least one compound of formula (III)

[0022]

[0024] wherein x is an integer in the range of ≥10 to ≤24 and y is an integer in the range of ≥10 to ≤25,

[0025] At least one compound of formula (VI)

[0026]

[0027] Where p is an integer in the range of ≥10 to ≤16,

[0028] At least one compound of formula (V)

[0029]

[0030] wherein A and B are each independently a hydrogen atom or an alkali metal or an alkaline earth metal, and

[0031] R is a linear or branched, saturated or unsaturated C 10 -C 20 aliphatic groups, and

[0032] At least one compound of formula (VI)

[0033]

[0034] wherein r is an integer in the range of ≥9 to ≤18, and M is a hydrogen atom, an alkali earth metal, or an alkaline earth metal.

[0035] In another aspect, the present invention relates to the use of at least one liquid crystal lipid particle for reducing the adhesion of dust to the skin, wherein

[0036] The liquid crystal lipid particles comprise compounds represented by general formulae (I) to (VI),

[0037] include,

[0038] At least one compound of formula (I)

[0039]

[0040] wherein m is an integer in the range of ≥10 to ≤24 and n is an integer in the range of ≥1 to ≤25,

[0041] At least one compound of formula (II)

[0042]

[0043] wherein a is an integer in the range of ≥10 to ≤24,

[0044] at least one compound of formula (III),

[0045]

[0046] wherein x is an integer in the range of ≥10 to ≤24 and y is an integer in the range of ≥10 to ≤25,

[0047] At least one compound of formula (IV)

[0048]

[0049] Where p is an integer in the range of ≥10 to ≤16,

[0050] At least one compound of formula (V)

[0051]

[0052] wherein A and B are each independently a hydrogen atom or an alkali metal or an alkaline earth metal, and

[0053] R is a linear or branched, saturated or unsaturated C 10 -C 20 Aliphatic groups,

[0054] and

[0055] At least one compound of formula (VI)

[0056]

[0057] wherein r is an integer in the range of ≥9 to ≤18, and M is a hydrogen atom, an alkali metal, or an alkaline earth metal.

[0058] Another aspect of the invention relates to a topical composition comprising at least one liquid crystal particle as described above and below, at least one thickener and water. BRIEF DESCRIPTION OF THE DRAWINGS

[0059] Figure 1 : Orthogonal lateral stacking of liquid crystal lipid particles,

[0060] Figure 2 : Figure showing transparent / flexible lipid membranes formed by processing liquid crystal lipid particles,

[0061] Figure 3 : The membrane formed by liquid crystal lipid particles has a repellent effect,

[0062] Figure 4 :The film formed by liquid crystal lipid particles has an anti-adhesion effect,

[0063] Figure 5 : The moisturizing effect of the composition comprising liquid crystal lipid particles was increased when measured on a skin moisture tester. DETAILED DESCRIPTION

[0064] Before describing the compositions and preparations of the present invention, it should be understood that the present invention is not limited to the specific compositions and preparations described, as such compositions and preparations may of course vary. It should also be understood that the terminology used herein is not intended to be limiting, as the scope of the present invention will be limited only by the appended claims.

[0065] If the definition group includes at least a certain number of embodiments hereinafter, this means that it also includes a group preferably consisting of only these embodiments. In addition, the terms "first", "second", "third" or "a", "b", "c" etc. in the specification and claims are used to distinguish similar elements, rather than being necessarily used to describe order or chronological order. It should be understood that the terms used in this way are interchangeable where appropriate, and the embodiments of the present invention described herein can be operated in other orders different from those described or illustrated herein. If the terms "first", "second", "third" or "(A)", "(B)" and "(C)" or "(a)", "(b)", "(c)", "(d)", "i", "ii" etc. relate to the steps of method or use or measurement, there is no time or time interval coherence between these steps, that is, these steps can be carried out simultaneously or the time interval between these steps may be seconds, minutes, hours, days, weeks, months or even years, unless otherwise specified in the application described above or below.

[0066] In addition, ranges defined throughout the specification are also inclusive, i.e., a range of 1 to 10 means that both 1 and 10 are included in the range. For the avoidance of doubt, the applicant is entitled to any equivalents under applicable law.

[0067] In the following paragraphs, different aspects of the present invention are defined in more detail. Unless explicitly stated otherwise, each aspect so defined can be combined with any other aspect or aspects. In particular, any feature indicated as being preferred or advantageous can be combined with any other feature indicated as being preferred or advantageous.

[0068] References to "one embodiment" or "an embodiment" throughout the specification mean that a particular feature, structure, or characteristic described in conjunction with the embodiment is included in at least one embodiment of the present invention. Therefore, the phrases "in one embodiment" or "in an embodiment" appearing in various places in this specification do not necessarily all refer to the same embodiment, but may. In addition, in one or more embodiments, the particular features, structures, or characteristics may be combined in any suitable manner, as will be apparent to those skilled in the art from this disclosure. In addition, although some embodiments described herein include some but not other features in other embodiments, the combination of features of different embodiments is intended to be within the scope of the present invention and to form different embodiments, as will be understood by those skilled in the art. For example, in the appended claims, any claimed embodiment may be used in any combination.

[0069] "Topical application" means applying or spreading the composition directly onto the skin surface of the human or animal body, preferably the face, scalp, feet, limbs or trunk.

[0070] The present invention relates to a method for reducing the adhesion of dust to the skin, the method comprising applying to the skin at least one liquid crystal lipid particle,

[0071] wherein the liquid crystal lipid particles comprise compounds represented by general formulae (I) to (VI),

[0072] include

[0073] At least one compound of formula (I)

[0074]

[0075] wherein m is an integer in the range of ≥10 to ≤24 and n is an integer in the range of ≥1 to ≤25,

[0076] At least one compound of formula (II)

[0077]

[0078] wherein a is an integer in the range of ≥10 to ≤24,

[0079] at least one compound of formula (III),

[0080]

[0081] wherein x is an integer in the range of ≥10 to ≤24 and y is an integer in the range of ≥10 to ≤25,

[0082] At least one compound of formula (IV)

[0083]

[0084] Where p is an integer in the range of ≥10 to ≤16,

[0085] At least one compound of formula (V)

[0086]

[0088] wherein A and B are each independently a hydrogen atom or an alkali metal or an alkaline earth metal, and

[0089] R is a linear or branched, saturated or unsaturated C 10 -C 20 Aliphatic groups,

[0090] and

[0091] At least one compound of formula (VI)

[0092]

[0093] wherein r is an integer in the range of ≥9 to ≤18, and M is a hydrogen atom, an alkali metal, or an alkaline earth metal.

[0094] In one embodiment, the present invention relates to the use of at least one liquid crystal lipid particle for reducing the adhesion of dust to the skin, wherein

[0095] The liquid crystal lipid particles comprise compounds represented by general formulae (I) to (VI),

[0096] include

[0097] At least one compound of formula (I)

[0098]

[0099] wherein m is an integer in the range of ≥10 to ≤24 and n is an integer in the range of ≥1 to ≤25,

[0100] At least one compound of formula (II)

[0101]

[0102] wherein a is an integer in the range of ≥10 to ≤24,

[0103] at least one compound of formula (III),

[0104]

[0105] wherein x is an integer in the range of ≥10 to ≤24 and y is an integer in the range of ≥10 to ≤25,

[0106] At least one compound of formula (IV)

[0107]

[0108] Where p is an integer in the range of ≥10 to ≤16,

[0109] At least one compound of formula (V)

[0110]

[0112] wherein A and B are each independently a hydrogen atom or an alkali metal or an alkaline earth metal, and

[0113] R is a linear or branched, saturated or unsaturated C 10 -C 20 Aliphatic groups,

[0114] and

[0115] At least one compound of formula (VI)

[0116]

[0117] wherein r is an integer in the range of ≥9 to ≤18, and M is a hydrogen atom, an alkali metal, or an alkaline earth metal.

[0118] In one embodiment of the invention, the topical composition comprises at least one liquid crystal particle as defined above, at least one thickener and water.

[0119] The liquid crystal lipid particles of the present invention comprise at least one compound selected from the group consisting of compounds represented by general formulae (I) to (IV),

[0120]

[0121] wherein m is an integer in the range of ≥10 to ≤24 and n is an integer in the range of ≥1 to ≤25,

[0122]

[0123] wherein a is an integer in the range of ≥10 to ≤24,

[0124]

[0125] wherein x is an integer in the range of ≥10 to ≤24 and y is an integer in the range of ≥10 to ≤25, and

[0126]

[0127] wherein p is an integer in the range of ≥10 to ≤16.

[0128] The liquid crystal particles of the present invention comprise at least one compound selected from the compounds represented by the general formulae (I) to (IV), and in addition at least one compound represented by the general formula (V) or (VI)

[0129]

[0130] A and B are each independently a hydrogen atom or an alkali metal or an alkaline earth metal, and R is a linear or branched, saturated or unsaturated C 10 -C 20 Aliphatic group.

[0131]

[0132] wherein r is an integer in the range of ≥9 to ≤18, and M is a hydrogen atom, an alkali metal, or an alkaline earth metal.

[0133] In one embodiment of the present invention, the liquid crystal lipid particles comprise at least one compound represented by the general formula (I) and at least one compound selected from the group consisting of compounds represented by the general formulae (II), (III) and (IV).

[0134] In one embodiment of the present invention, the liquid crystal lipid particles comprise at least one compound represented by the general formula (I) and at least one compound selected from the group consisting of compounds represented by the general formulae (II), (III), (IV), (V) and (VI).

[0135] In another embodiment of the present invention, the liquid crystal lipid particles comprise at least one compound represented by the general formula (II) and at least one compound selected from the group consisting of compounds represented by the general formulae (I), (III) and (IV).

[0136] In another embodiment of the present invention, the liquid crystal lipid particles comprise at least one compound represented by the general formula (II) and at least one compound selected from the compounds represented by the general formulas (I), (III), (IV), (V) and (VI).

[0137] In another embodiment of the present invention, the liquid crystal lipid particles comprise at least one compound represented by the general formula (III) and at least one compound selected from the group consisting of compounds represented by the general formulae (I), (II) and (IV).

[0138] In another embodiment of the present invention, the liquid crystal lipid particles comprise at least one compound represented by the general formula (III) and at least one compound selected from the compounds represented by the general formulas (I), (II), (IV), (V) and (VI).

[0139] In another embodiment of the present invention, the liquid crystal lipid particles comprise at least one compound represented by the general formula (IV) and at least one compound selected from the compounds represented by the general formulas (I), (II), (III), (V) and (VI).

[0140] In another embodiment of the present invention, the liquid crystal lipid particles comprise at least one compound represented by the general formula (I) and at least one compound represented by the general formula (II) and at least one compound represented by the general formula (III) and at least one compound represented by the general formula (IV).

[0141] In another embodiment of the present invention, the liquid crystal lipid particles contain at least one compound represented by general formula (I) and at least one compound represented by general formula (II) and at least one compound represented by general formula (III) and at least one compound represented by general formula (IV) and at least one compound represented by general formula (V).

[0142] In another embodiment of the present invention, the liquid crystal lipid particles contain at least one compound represented by general formula (I) and at least one compound represented by general formula (II) and at least one compound represented by general formula (III) and at least one compound represented by general formula (IV) and at least one compound represented by general formula (VI).

[0143] In another embodiment of the present invention, the liquid crystal lipid particles comprise at least one compound represented by the general formula (I), at least one compound represented by the general formula (II), at least one compound represented by the general formula (III), at least one compound represented by the general formula (IV), at least one compound represented by the general formula (VI), at least one compound represented by the general formula (V), and at least one compound represented by the general formula (VI).

[0144] In one embodiment of the present invention, the liquid crystal lipid particles comprise at least one compound represented by the general formula (I):

[0145]

[0146] wherein m is an integer in the range of ≥10 to ≤24 and n is an integer in the range of ≥1 to ≤25.

[0147] In one embodiment of the present invention, at least one compound of formula (I) is selected from ceteareths, polyoxyethylene stearyl ethers and polyoxyethylene cetyl ethers.

[0148] In one embodiment of the present invention, at least one compound of formula (I) is selected from ceteareth-20, ceteareth-12, ceteareth-30.

[0149] In the most preferred embodiment of the present invention, at least one compound of general formula (I) is selected from ceteareth-20, ce-teareth-12.

[0150] In one embodiment of the present invention, in at least one compound of formula (II),

[0151]

[0152] wherein a is an integer in the range of ≥10 to ≤24,

[0153] In one embodiment of the present invention, at least one compound of general formula (II) is selected from glyceryl stearate, glyceryl laurate and glyceryl palmitate, glyceryl caprylate, glyceryl myristate.

[0154] In a preferred embodiment of the present invention, the at least one compound of the general formula (II) is glyceryl stearate.

[0155] In one embodiment of the present invention, in at least one compound of formula (III),

[0156]

[0157] wherein x is an integer in the range of ≥10 to ≤24 and y is an integer in the range of ≥10 to ≤25,

[0158] In one embodiment of the present invention, at least one compound of formula (III) is selected from the group consisting of myristyl myristate, myristyl palmitate, myristyl stearate, myristyl isostearate, myristyl oleate, myristyl behenate, myristyl erucate, cetyl myristate, cetyl palmitate, cetyl stearate, cetyl isostearate, cetyl oleate, cetyl behenate, cetyl erucate, stearyl myristate, stearyl palmitate, stearyl stearate, stearyl isostearate, stearyl oleate, stearyl behenate, stearyl erucate, myristyl Isostearyl myristate, isostearyl palmitate, isostearyl stearate, isostearyl isostearate, isostearyl oleate, isostearyl behenate, isostearyl oleate, oleyl myristate, oleyl palmitate, oleyl stearate, oleyl isostearate, oleyl oleate, oleyl behenate, oleyl erucate, behenyl myristate, behenyl palmitate, behenyl stearate, behenyl isostearate, behenyl oleate, behenyl behenate, behenyl erucate, erucyl myristate, erucyl palmitate, erucyl stearate, erucyl isostearate, erucyl oleate, erucyl behenate and erucyl erucate.

[0159] In another embodiment of the present invention, at least one compound of formula (III) is selected from cetyl palmitate, myristyl myristate, myristyl myristate and behenyl behenate.

[0160] In a preferred embodiment of the present invention, at least one compound of the general formula (III) is selected from cetyl palmitate, myristyl myristate.

[0161] In one embodiment of the present invention, in at least one compound of the general formula (IV),

[0162]

[0163] wherein p is an integer in the range of ≥10 to ≤16.

[0164] In yet another embodiment of the present invention, the at least one compound of formula (IV) is selected from lauryl alcohol, tridecanol, myristyl alcohol, pentadecanol, cetyl alcohol, palmitoleyl alcohol, heptadecanol and stearyl alcohol or mixtures thereof.

[0165] In a preferred embodiment of the present invention, the at least one compound of the general formula (IV) is selected from lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol or mixtures thereof.

[0166] In a most preferred embodiment of the present invention, the at least one compound of formula (IV) is a mixture of cetyl alcohol and stearyl alcohol.

[0167] In one embodiment of the present invention, in at least one compound of formula (V),

[0168]

[0169] A and B are each independently a hydrogen atom or an alkali metal or an alkaline earth metal, and R is a linear or branched, saturated or unsaturated C 10 -C 20 Aliphatic group.

[0170] In one embodiment of the present invention, in at least one compound of formula (V), A and B are each independently an alkali metal, and R is a linear or branched, saturated or unsaturated C 10 -C 20 Aliphatic group.

[0171] In another embodiment of the present invention, in at least one compound of formula (V), R is n-decyl, isodecyl, n-undecyl, isoundecyl, n-dodecyl, isododecyl, n-tridecyl, isotridecyl, n-tetradecyl, isotetradecyl, n-pentadecyl, isopentadecyl, n-hexadecyl, isohexadecyl, n-heptadecyl, isoheptadecyl, n-octadecyl, isooctadecyl and n-octadecenyl.

[0172] In another embodiment of the present invention, at least one compound of formula (V) is C 10 -C 18 Disodium alkyl sulfosuccinate.

[0173] In a preferred embodiment of the present invention, at least one compound of formula (V) is C 12 -C 18 Disodium alkyl sulfosuccinate.

[0174] In the most preferred embodiment of the present invention, at least one compound of formula (V) is C 16 -C 18 Alkyl sulfosuccinates.

[0175] In one embodiment of the present invention, in at least one compound of formula (VI),

[0176]

[0177] wherein r is an integer in the range of ≥9 to ≤18, and M is a hydrogen atom, an alkali metal, or an alkaline earth metal.

[0178] In one embodiment of the invention, in at least one compound of the general formula (VI), M is sodium or potassium and r is an integer in the range of ≧9 to ≦18.

[0179] In one embodiment of the present invention, at least one compound of formula (VI) is selected from sodium stearoyl glutamate, sodium lauroyl glutamate, sodium cocoyl glutamate, sodium myristoyl glutamate, potassium cocoyl glutamate, potassium lauroyl glutamate and combinations thereof.

[0180] In one embodiment of the present invention, the at least one compound of formula (VI) is selected from sodium lauroyl glutamate, sodium cocoyl glutamate, sodium myristoyl glutamate and sodium stearoyl glutamate.

[0181] In one embodiment of the invention, the crystalline lipid particles comprise ceteareths, glyceryl stearate, cetyl palmitate, cetyl alcohol and stearyl alcohol.

[0182] In yet another embodiment of the present invention, the liquid crystal lipid particles include ceteareths, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol and stearyl alcohol.

[0183] In another embodiment of the present invention, the liquid crystal lipid particles comprise ceteareths, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol, stearyl alcohol and a mixture selected from C10 -C 18 Compound of disodium alkyl sulfosuccinate and sodium stearoyl glutamate.

[0184] In a preferred embodiment of the present invention, the liquid crystal lipid particles include ceteareth-20, ceteareth-12, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol, stearyl alcohol and a mixture selected from C 16 -C 18 Compound of disodium alkyl sulfosuccinate and sodium lauroyl glutamate.

[0185] In another preferred embodiment of the present invention, the liquid crystal lipid particles include ceteareth-20, ceteareth-12, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol, stearyl alcohol and a mixture selected from C 12 -C 14 Compound of disodium alkyl sulfosuccinate and sodium lauroyl glutamate.

[0186] In another preferred embodiment of the present invention, the liquid crystal lipid particles comprise ceteareth-20, ceteareth-12, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol, stearyl alcohol and a mixture selected from C 12 -C 14 Compound of disodium alkyl sulfosuccinate and sodium stearoyl glutamate.

[0187] In a most preferred embodiment of the present invention, the liquid crystal lipid particles include ceteareth-20, ceteareth-12, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol, stearyl alcohol and selected from C 16 -C 18 Compound of disodium alkyl sulfosuccinate and sodium stearoyl glutamate.

[0188] In one embodiment of the invention, the liquid crystal lipid particles have an average particle size of ≥20 nm to ≤500 nm, as measured using dynamic light scattering using a Malvern DLS ZS90.

[0189] In one embodiment of the invention, the liquid crystal lipid particles have an average particle size of ≥20 nm to ≤300 nm, as measured using dynamic light scattering using a Malvern DLS ZS90.

[0190] In one embodiment of the invention, the liquid crystal lipid particles have an average particle size of ≥20 nm to ≤150 nm, as measured using dynamic light scattering using a Malvern DLS ZS90.

[0191] In one embodiment of the present invention, the average particle size of the liquid crystal lipid particles is 20 nm, 30 nm, 40 nm, 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 110 nm, 120 nm, 130 nm, 140 nm or 150 nm, as measured using dynamic light scattering using a Malvern DLS ZS90.

[0192] The zeta potential of liquid crystal lipid particles is a measure of the surface charge of the particles and a measure of the stability of the lipid particles. The higher the zeta potential, the higher the stability.

[0193] In one embodiment of the invention, the liquid crystal lipid particles have a zeta potential greater than 20 mV when measured at 40°C.

[0194] In one embodiment of the invention, the liquid crystal lipid particles have a zeta potential greater than 30 mV when measured at 40°C.

[0195] In one embodiment of the present invention, the liquid crystal lipid particles are prepared by using the phase inversion temperature method.

[0196] In another embodiment of the present invention, liquid crystal lipid particles are prepared using the phase inversion temperature method as disclosed in DJ Mitchell et al., Phase behavior of polyoxyethylene surfactants with water, Mesophase structures and partial miscibility (cloud points), J. Chem. Soc. Fairayday Trans., 79, 975-1000 (1983), which is incorporated herein by reference.

[0197] In one embodiment of the invention, the liquid crystal lipid particles have orthogonal lateral packing.

[0198] In one embodiment of the invention, the liquid crystal lipid particles are comprised in a topical composition for application to the skin.

[0199] In one embodiment of the invention, the liquid crystal lipid particles form the base for any topical composition for application to the skin.

[0200] In one embodiment of the invention, the at least one liquid crystal lipid particle is present in an amount ranging from ≥ 1% to ≤ 30% by weight, based on the total weight of the topical composition.

[0201] In another embodiment of the present invention, the at least one liquid crystal lipid particle is present in an amount of ≥ 1% to ≤ 25% by weight, based on the total weight of the topical composition.

[0202] In a preferred embodiment of the present invention, the at least one liquid crystal lipid particle is present in an amount of ≥1% to ≤20% by weight, based on the total weight of the topical composition.

[0203] In a most preferred embodiment of the present invention, the at least one liquid crystal lipid particle is present in an amount of ≥ 1% to ≤ 15% by weight, based on the total weight of the topical composition.

[0204] In one embodiment of the invention, the topical composition is in the form of a cream, foam, lotion, gel, paste, spray, patch, spray patch, mousse or ointment.

[0205] In one embodiment of the present invention, the topical composition further comprises at least one auxiliary agent selected from the group consisting of anti-wrinkle active agents, anti-acne active agents, emulsifiers, antioxidants, emollients, self-tanning active agents, skin lightening agents, sunscreens, UV absorbers, thickeners, humectants, abrasives, absorbents, fragrances, buffers, sunscreens, colorants, preservatives, fillers, pH adjusters and solvents.

[0206] In one embodiment of the invention, the active agent is selected from anti-wrinkle agents such as retinol, hyaluronic acid, ceramide, niacinamide, vitamin E, alpha-hydroxy acids, anti-acne agents such as clindamycin, benzamycin, benzoyl peroxide and isotretinoin.

[0207] In one embodiment of the present invention, the skin lightening agent is selected from the group consisting of tretinoin, hydroquinone, resorcinol, arbutin, kojic acid, azelaic acid, vitamin C, glutathione and alpha-hydroxy acids.

[0208] In one embodiment of the present invention, the UV absorber or sunscreen is selected from suitable sunscreens, including, for example: p-aminobenzoic acid, its salts and derivatives thereof (ethyl, isobutyl, glyceryl esters; p-dimethylaminobenzoic acid, diethylaminohydroxybenzoyl hexyl benzoate); anthranilates (i.e., anthranilates; methyl, menthyl, phenyl, benzyl, phenethyl, linalyl, terpinate and cyclohexenyl esters); salicylates (amyl, phenyl, benzyl, menthyl esters, terpineol ... esters, glycerides and dipropylene glycol esters); cinnamic acid derivatives (menthyl and benzyl esters, butylcinnamylpyruvate); dihydroxycinnamic acid derivatives (umbelliferone, methylumbelliferone, methylacetylumbelliferone); trihydroxycinnamic acid derivatives (esculetin, methylgeraniol, daphnetin and glycosides, esculetin and daphnetin); hydrocarbons (diphenylbutadiene, stilbene); dibenzylideneacetone and benzylideneacetophenone; naphthol sulfonates (2-naphthol-3,6-disulfonic acid and 2-naphthol -6,8-disulfonic acid, sodium salt); dihydroxynaphthoic acid and its salts; o- and p-hydroxybiphenyl disulfonates; coumarin derivatives (7-hydroxy, 7-methyl, 3-phenyl); diazoles (2-acetyl-3-bromoindazole, phenylbenzoxazole, methylnaphthoxazole, various arylbenzothiazoles); quinine salts (bisulfate, sulfate, chloride, oleate and tannate); hydroxy- or methoxy-substituted benzophenones; uric acid and violuric acid; tannic acid and its derivatives (e.g., hexaethyl ether); (butylcarboxol)(6-propylpiperonyl) ether; benzophenone (oxybenzone, sulisobenzone, dioxybenzophenone, benzoresorcinol, 2,2',4,4'-tetrahydroxybenzophenone, 2,2'-dihydroxy-4,4'-dimethoxybenzophenone, octabenzophenone; 4-isopropyldibenzoylmethane; butylmethoxydibenzoylmethane; and tetramethylbenzene; -isopropyl-di-benzoylmethane.

[0209] In a preferred embodiment of the present invention, the UV absorber or sunscreen is selected from 2-ethylhexyl-p-methoxycinnamate, 4,4'-tert-butylmethoxydibenzoyl-methane, 2-hydroxy-4-methoxybenzophenone, octyldimethyl-p-aminobenzoic acid, digalloyl trioleate, 2,2-dihydroxy-4-methoxybenzophenone, 4 (bis (hydroxypropyl)) aminobenzoic acid ethyl ester, 2-ethylhexyl-2-cyano-3,3- Diphenylacrylate, 2-ethylhexyl salicylate, glyceryl-p-aminobenzoate, 3,3,5-trimethylcyclohexyl salicylate, methyl anthranilate, p-dimethyl-aminobenzoic acid or aminobenzoic acid ester, 2-ethylhexyl-p-dimethyl-amino-benzoate, 2-phenylbenzimidazole-5-sulfonic acid, 2-(p-dimethylaminophenyl)-5-sulfonic acid benzoxazolyl acid, methylene bis-benzotriazolyl tetramethylbutylphenol and mixtures thereof.

[0210] In one embodiment of the invention, the thickener is selected from polymeric thickeners, including nonionic thickeners and anionic thickeners, or mixtures thereof. Suitable nonionic thickeners include polyacrylamide polymers, crosslinked poly(N-vinyl pyrrolidone), polysaccharides, natural or synthetic gums or polysaccharides, polyvinyl pyrrolidone and polyvinyl alcohol. Suitable anionic thickeners include acrylic acid / ethyl acrylate copolymers, carboxyvinyl polymers and crosslinked copolymers of alkyl vinyl ethers and maleic anhydride.

[0211] In one embodiment of the present invention, the thickener is selected from polysaccharides including cellulose, carboxymethyl hydroxyethyl cellulose, cellulose acetate propionate carboxylate, hydroxyethyl cellulose, hydroxyethyl ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl hydroxyethyl cellulose, microcrystalline cellulose, sodium cellulose sulfate and mixtures thereof, natural gums such as gum arabic, agar, alginic acid, ammonium alginate, pullulan, calcium alginate, calcium carrageenan, carnitine, carrageenan, dextrin, gelatin, gelatin, guar gum, guar hydroxypropyltrimonium chloride, hectorite, hyaluronic acid, hydrated silica, hydroxypropyl chitosan, hydroxypropyl guar gum, karaya gum, kelp, locust bean gum, natto gum, potassium alginate, potassium carrageenan, propylene glycol alginate, sclerotium gum, sodium carboxymethyl dextran, sodium carrageenan, tragacanth gum, xanthan gum and mixtures thereof. In one embodiment of the present invention, the moisturizer is selected from sodium 2-pyrrolidone-5-carboxylate (NaPCA), guanidine, glycolic acid and glycolate salts (e.g., ammonium and quaternary alkyl ammonium), lactic acid and lactate salts (e.g., ammonium and quaternary alkyl ammonium), aloe vera in any form (e.g., aloe vera gel), hyaluronic acid and its derivatives (e.g., salt derivatives, such as sodium hyaluronate), lactamide monoethanolamine, acetamide monoethanolamine, urea, panthenol and its derivatives, and mixtures thereof.

[0212] In one embodiment of the invention, the buffer is selected from the group consisting of lactic acid, lactate, gluconic acid, glucono-delta-lactone, sodium and potassium gluconate, trisodium citrate, tripotassium citrate, sodium lactate and potassium lactate,

[0213] In one embodiment of the present invention, the solvent is selected from polyols, including glycerol, diglycerol, triglycerol, polyglycerol, polypropylene glycol, polyethylene glycol, ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, hexylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, ethylene glycol monoalkyl ether, diethylene glycol monoalkyl ether, glucose, maltose, sucrose, lactose, xylose, xylitol, sorbitol, mannitol, maltitol, maltose, panthenol, pentaerythritol, hyaluronic acid and its salts, water, ethanol and isopropanol.

[0214] In one embodiment of the present invention, the solvent is selected from glycerol, water and ethanol.

[0215] In one embodiment of the present invention, the preservative is selected from benzalkonium chloride, benzethonium chloride, benzyl alcohol, caprylyl glycol, chlorphenesin, 2,2'-dithiobis(N-methylbenzamide), diazolidinyl urea, ethylenediaminetetraacetic acid, ethyl paraben, imidazolidinyl urea, methyl paraben, phenoxy-ethanol, linoleamidopropyl PG-diammonium chloride phosphate, cocamidopropyl PG-diammonium chloride phosphate, propyl paraben, cis-l-(3-chloroallyl)-3,5,7-triaza-l-azaadamantane chloride, dehydroacetic acid or a salt thereof, benzoic acid or a salt thereof, sodium hydroxymethylglycinate and zinc pyrithione.

[0216] In one embodiment of the present invention, the liquid crystal lipid particles are comprised in a topical composition further comprising a sunscreen, a UV absorber, a thickener and a solvent.

[0217] In a preferred embodiment of the present invention, the liquid crystal lipid particles are contained in a topical composition which further comprises diethylamino hydroxybenzoyl hexyl benzoate, ethylhexyl methoxycinnamate, acrylates / beheneth-25 methacrylate copolymer, methylene bis-benzotriazolyltetramethylbutylphenol, decyl glucoside, propylene glycol and xanthan gum, ethanol, water and butylene glycol.

[0218] The effects of the compositions of the present invention in achieving barrier repair or maintaining the integrity of the outer layer of the skin can be applied to a variety of different uses. For example, the compositions can be used to treat any condition in which a defective or impaired barrier is a factor. In this regard, the compositions can be used to improve the long-term moisturization of the skin, or to prevent or treat dry skin conditions in general, or dry skin conditions in particular, such as those caused by regular exposure to detergents, soaps, and hot water; seasonal exposure to adverse weather conditions, such as cold, wind, and / or sunlight; occupational exposure to irritating chemicals or other drying or damaging agents; or pathological conditions such as eczematous dermatitis, psoriasis, ichthyosis, xerosis, etc.

[0219] As is well known, dry skin is often associated with aging (intrinsic aging and photoaging), and the composition can be used to prevent further damage to aged skin, or to treat and / or reverse existing damage, including the appearance of fine lines and wrinkles, which are often associated with dry skin and the thinning of the stratum corneum that occurs with age. The composition can also be used to treat a defective skin barrier, such as occurs on the soles of the feet and palms of the hands, where the stratum corneum is very thick but the lipid barrier is poor. In addition, a defective skin barrier is often associated with burns, wounds, blisters, stasis ulcers, and bedsores; such injuries are expected to benefit from the use of the composition.

[0220] The compositions of the present invention can be used to reduce the skin's response to irritants and sensitizers. A large portion of the population has sensitive skin because they have frequent, stinging or painful reactions to various elements that the skin may come into contact with, whether through cosmetic or skin care products, environmental irritants such as smoke or pollution, or occupational exposure to chemicals. In addition, even normal skin can react to exposure to known irritants such as acids.

[0221] As is well known, the stratum corneum and lipids constitute the first line of defense against irritants. By providing a physical barrier to the penetration of such materials into the lower skin layers, the application of the composition of the present invention can reduce the reactivity of the skin of normal and sensitive individuals to irritants and sensitizers by increasing the integrity of the barrier. For example, in one embodiment, the composition can be used to reduce the skin's response to irritation caused by therapeutic acids such as α- and β-hydroxy acids, retinoic acid, etc., or to reduce irritation caused by insect bites or stings, or to alleviate irritation caused by contact dermatitis.

[0222] The compositions of the present invention are used in a manner appropriate to the end use of the product. For example, in the treatment of occasional dry skin due to exposure to weather or other temporary conditions, or in the treatment of occasional skin irritation, the composition can be used as needed until the condition is relieved. When used to treat more persistent conditions, such as those associated with lipid barrier defects or deficiencies, particularly sensitive skin, dry skin associated with any type of aging, or wrinkles or fine lines associated with thinning of the stratum corneum due to aging, long-term use is preferred to prevent recurrence of the condition.

[0223] In one embodiment, the composition of the present invention may be present in an amount of about 0.1 mg / cm 2 Up to 2mg / cm 2 The amount is applied to the skin from about once a week to about 4 or 5 times a day, preferably about 3 times a week to about 3 times a day, and most preferably about once or twice a day.

[0224] Furthermore, the compositions of the present invention can be administered for longer durations, preferably for at least about one month, about three months to about twenty years, more preferably about six months to about ten years, more preferably from about one year to about five years, thereby resulting in treatment or prevention of the condition in question.

[0225] advantage:

[0226] 1. Liquid crystal lipid particles have a certain shape, thus mimicking the skin structure.

[0227] 2. The composition containing liquid crystal lipid particles forms a flexible film on the skin, protects the skin from pollutants, and has a moisturizing effect on the skin.

[0228] 3. The liquid crystal lipid particle composition is stable under different temperature conditions. DETAILED DESCRIPTION

[0230] 1. A method for reducing dust adhesion to the skin, comprising applying at least one liquid crystal lipid particle to the skin,

[0231] The liquid crystal lipid particles comprise compounds represented by general formulae (I) to (VI),

[0232] include,

[0233] At least one compound of formula (I)

[0234]

[0235] wherein m is an integer in the range of ≥10 to ≤24 and n is an integer in the range of ≥1 to ≤25,

[0236] At least one compound of formula (II)

[0237]

[0238] wherein a is an integer in the range of ≥10 to ≤24,

[0239] At least one compound of formula (III)

[0240]

[0241] wherein x is an integer in the range of ≥10 to ≤24 and y is an integer in the range of ≥10 to ≤25,

[0242] At least one compound of formula (IV)

[0243]

[0244] Where p is an integer in the range of ≥10 to ≤16,

[0245] At least one compound of formula (V)

[0246]

[0247] wherein A and B are each independently a hydrogen atom or an alkali metal or an alkaline earth metal, and

[0248] R is a linear or branched, saturated or unsaturated C 10 -C 20 Aliphatic groups,

[0249] and

[0250] At least one compound of formula (VI)

[0251]

[0252] wherein r is an integer in the range of ≥9 to ≤18, and M is a hydrogen atom, an alkali metal, or an alkaline earth metal.

[0253] 2. Use of at least one liquid crystal lipid particle for reducing the adhesion of dust to the skin, wherein the liquid crystal lipid particle comprises a compound represented by general formula (I) to (VI),

[0254] include,

[0255] At least one compound of formula (I)

[0256]

[0257] wherein m is an integer in the range of ≥10 to ≤24 and n is an integer in the range of ≥1 to ≤25,

[0258] At least one compound of formula (II)

[0259]

[0260] wherein a is an integer in the range of ≥10 to ≤24,

[0261] At least one compound of formula (III)

[0262]

[0263] wherein x is an integer in the range of ≥10 to ≤24 and y is an integer in the range of ≥10 to ≤25,

[0264] At least one compound of formula (IV)

[0265]

[0266] Where p is an integer in the range of ≥10 to ≤16,

[0267] At least one compound of formula (V)

[0268]

[0269] wherein A and B are each independently a hydrogen atom or an alkali metal or an alkaline earth metal, and

[0270] R is a linear or branched, saturated or unsaturated C 10 -C 20 Aliphatic groups,

[0271] and

[0272] At least one compound of formula (VI)

[0273]

[0274] wherein r is an integer in the range of ≥9 to ≤18, and M is a hydrogen atom, an alkali metal, or an alkaline earth metal.

[0275] 3. The method or use according to embodiment 1 or 2, wherein the liquid crystal lipid particles have a lamellar structure with orthogonal lateral stacking.

[0276] 4. The method or use according to embodiment 1 or 2, wherein the liquid crystal lipid particles have an average particle size of ≥20 nm to ≤300 nm as measured by dynamic light scattering using a Malvern DLS ZS90.

[0277] 5. The method or use according to embodiment 1 or 2, wherein the liquid crystal lipid particles have a zeta potential greater than 20 mV.

[0278] 6. The method or use according to embodiments 1 to 5, wherein at least one compound of general formula (I) is selected from cetearyl alcohol polyether, polyoxyethylene stearyl ether and polyoxyethylene cetyl ether.

[0279] 7. The method or use according to embodiments 1 to 6, wherein at least one compound of general formula (II) is selected from glyceryl stearate, glyceryl laurate and glyceryl palmitate.

[0280] 8. The method or use according to embodiments 1 to 7, wherein at least one compound of general formula (III) is selected from cetyl palmitate, myristyl myristate, myristyl myristate and behenyl behenate.

[0281] 9. The method or use according to embodiments 1 to 8, wherein at least one compound of general formula (IV) is selected from lauryl alcohol, tridecanol, myristyl alcohol, pentadecanol, cetyl alcohol, palmityl alcohol, heptadecanol, stearyl alcohol or mixtures thereof.

[0282] 10. The method or use according to embodiments 1 to 9, wherein at least one compound of formula (V) is C 10 -C 18 Disodium alkyl sulfosuccinate.

[0283] 11. The method or use according to embodiments 1 to 10, wherein at least one compound of general formula (VI) is selected from sodium lauroyl glutamate, sodium cocoyl glutamate, sodium myristoyl glutamate and sodium stearoyl glutamate.

[0284] 12. The method or use according to one or more of embodiments 1 to 11, wherein the liquid crystal lipid particles comprise cetearyl alcohol polyether, glyceryl stearate, cetyl palmitate, cetyl alcohol and stearyl alcohol.

[0285] 13. The use according to one or more of embodiments 1 to 11, wherein the liquid crystal lipid particles comprise ceteareth, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol and stearyl alcohol.

[0286] 14. The use according to one or more of embodiments 1 to 11, wherein the liquid crystal lipid particles comprise cetearyl alcohol polyether, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol, stearyl alcohol and a mixture selected from C 10 -C 18 Compound of disodium alkyl sulfosuccinate and sodium stearoyl glutamate.

[0287] 15. The use according to one or more of embodiments 1 to 11, wherein the liquid crystal lipid particles comprise ceteareth-20, ceteareth-12, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol, stearyl alcohol and a mixture selected from C 16 -C 18 Compound of disodium alkyl sulfosuccinate and sodium stearoyl glutamate.

[0288] 16. A topical composition comprising,

[0289] at least one liquid crystal particle according to one or more of embodiments 1 to 15,

[0290] at least one thickener, and

[0291] water.

[0292] 17. The topical composition according to embodiment 16, wherein the at least one thickener is selected from the group consisting of xanthan gum, succinoglycans, gelatin, pectin, alginates, starches, guar gum, acrylates, acrylate copolymers, carbomers, and associative thickeners.

[0293] 18. The topical composition according to embodiment 16 or 17, wherein the at least one liquid crystal lipid particle is present in an amount of ≥1 wt % to ≤30 wt %, based on the total weight of the topical composition.

[0294] 19. The topical composition according to one or more of embodiments 16 to 18, wherein the at least one thickener is present in an amount of ≥ 0.1 wt.-% to ≤ 5 wt.-%, based on the total weight of the topical composition.

[0295] 20. The topical composition according to one or more of embodiments 16 to 19, wherein water is present in an amount of ≥5 wt.-% to ≤80 wt.-%, based on the total weight of the topical composition.

[0296] 21. The topical composition according to one or more of embodiments 16 to 20, further comprising at least one auxiliary agent selected from anti-wrinkle active agents, anti-acne active agents, emulsifiers, antioxidants, emollients, self-tanning active agents, skin lightening agents, sunscreens, moisturizers, abrasives, absorbents, fragrances, buffers, sunscreens, colorants, preservatives, fillers and pH adjusters.

[0297] 22. The topical composition according to one or more of embodiments 16 to 21, wherein the topical composition is a skin care composition.

[0298] 23. The topical composition according to one or more of embodiments 12 to 22, wherein the topical composition is in the form of a cream, foam, lotion, gel, paste or ointment.

[0299] 24. A method of reducing dust adhesion to the skin comprising applying to the skin a topical composition according to one or more of embodiments 16 to 23.

[0300] Example

[0301] The following examples are listed below to illustrate the methods and results according to the disclosed subject matter. These examples are not intended to include all aspects of the subject matter disclosed herein, but to illustrate representative methods, compositions and results. These examples are not intended to exclude equivalents and variants of the present invention, which will be apparent to those skilled in the art.

[0302] Material:

[0303] Materials from BASF:

[0304] · SE-PF is glyceryl stearate, ceteareth-20, ceteareth-12, cetyl alcohol, and cetyl palmitate is an emulsifying base.

[0305] · B1 is ceteareth-12 (cetearyl alcohol polyether, containing 12 mol EO), a nonionic emulsifier

[0306] · MM is myristyl myristate, an emollient

[0307] · Prisma is C 16 -C 18 Disodium alkyl sulfosuccinate, an anionic emulsifier

[0308] · SG is sodium stearoyl glutamate, which is an anionic emulsifier.

[0309] · A Plus is diethylamino hydroxybenzoyl hexyl benzoate, which is a UV absorber

[0310] · MC 80 is ethylhexyl methoxycinnamate, which is a UV absorber

[0311] · GTC is an acrylates / beheneth-25 methacrylate copolymer, a thickener or viscosity modifier

[0312] · XGN is a type of xanthan gum, which is a thickener or viscosity modifier.

[0313] · M is methylene bisbenzotriazolyl tetramethylbutylphenol, water, decyl glucoside, propylene glycol and xanthan gum, which is a UV filter

[0314] From Clariant

[0315] · Phenoxyethanol (and) methylparaben (and) ethylparaben (and) propylparaben (and) butylparaben (and) isobutylparaben, used as a broad-spectrum antimicrobial agent or preservative

[0316] method:

[0317] Particle size measurement: Particle size measurement of liquid crystal lipid particles was performed using a Malvern DLS ZS90.

[0318] Zeta potential measurement: Zeta potential was measured using Zetasizer nano ZS90 (Malvern)

[0319] Example 1

[0320] Basic components of liquid crystal lipid particles

[0321]

[0322]

[0323] qs = sufficient quantity

[0324] Manufacturing method: Phase inversion temperature emulsification method

[0325] 1) Heat the ingredients of Part A and Part B separately to 80°C.

[0326] 2) Add Part A to Part B and mix using a homogenizer until uniform to form a base.

[0327] 3) Mix Part C with the base from step 2.

[0328] 4) Cool the base formed in step 4 to room temperature in an ice bath.

[0329] 5) Add part D to the base and mix using a homogenizer until uniform.

[0330] result

[0331]

[0332] Example 2

[0333]

[0334]

[0335] Manufacturing method:

[0336] 1) Heat the ingredients of Part A and Part B separately to 80°C.

[0337] 2) Add Part A to Part B under homogenization and mix until uniform.

[0338] 3) Mix Part C with the mixture of Parts A and B and cool to 45°C.

[0339] 4) Add part D to the mixture from step 3 and mix using a homogenizer until uniform. Then cool it to room temperature.

[0340] Example 3

[0341] Dustproof performance-test plan

[0342] 1) 4 g of the composition according to Examples 2T1 to 2T3 were each applied to a PMMA plate.

[0343] 2) 2 g of the composition was further applied to the plate to ensure uniform distribution of the composition on the plate.

[0344] 3) Place the plate in a 38°C oven overnight.

[0345] 4) Place the plate upside down on a plate with a measured amount of dust and shake gently for 30 seconds.

[0346] 5) Turn the plate back over again and weigh the sand in the dish.

[0347] result

[0348] Dust adhesion Ex.3T1 Ex.3T2 Ex.3T3 33％ 22％ 27％

[0349] The lower dust adhesion in Example 3T2 demonstrates the excellent performance of the composition comprising liquid crystal lipid particles as a base.

[0350] Attached Figure 3 and 4 It was shown that dust adhesion on the skin surface was reduced after application of the composition comprising liquid crystal lipid particles.

[0351] Example 4

[0352] Test moisturizing effect

[0353]

[0354] Manufacturing method:

[0355] 1) Dissolve Part A at 80°C.

[0356] 2) Allow the base to cool to room temperature and then add Part B to the base. Mix until smooth.

[0357] Results: When measured on a keratometer, the composition of Example 4T5 has a three-fold increase in moisturizing effect compared to Example 4T4. Figure 5 The results for Example 4T4 are shown.

Claims

1. A method for reducing dust adhesion to the skin, comprising applying at least one liquid crystal lipid particle to the skin, wherein the liquid crystal lipid particles comprise compounds represented by general formulae (I) to (VI), include, At least one compound of formula (I) wherein m is an integer in the range of ≥10 to ≤24 and n is an integer in the range of ≥1 to ≤25, At least one compound of formula (II) wherein a is an integer in the range of ≥10 to ≤24, At least one compound of formula (III) wherein x is an integer in the range of ≥10 to ≤24 and y is an integer in the range of ≥10 to ≤25, At least one compound of formula (IV) Where p is an integer in the range of ≥10 to ≤16, At least one compound of formula (V) wherein A and B are each independently a hydrogen atom or an alkali metal or an alkaline earth metal, and R is a linear or branched, saturated or unsaturated C 10 -C 20 Aliphatic groups, and At least one compound of formula (VI) wherein r is an integer in the range of ≥9 to ≤18, and M is a hydrogen atom, an alkali metal or an alkaline earth metal, The liquid crystal lipid particles have a zeta potential greater than 20 mV.

2. The method according to claim 1, wherein the liquid crystal lipid particles have a lamellar structure with orthogonal lateral stacking.

3. The method of claim 1, wherein the liquid crystal lipid particles have an average particle size of ≥20 nm to ≤300 nm as measured by dynamic light scattering using a Malvern DLS ZS90.

4. The method according to any one of claims 1 to 3, wherein at least one compound of general formula (I) is selected from cetearyl alcohol polyether, polyoxyethylene stearyl ether and polyoxyethylene cetyl ether.

5. The process according to any one of claims 1 to 3, wherein at least one compound of general formula (II) is selected from glyceryl stearate, glyceryl laurate and glyceryl palmitate.

6. The method according to claim 4, wherein the at least one compound of general formula (II) is selected from glyceryl stearate, glyceryl laurate and glyceryl palmitate.

7. The method according to any one of claims 1 to 3, wherein at least one compound of general formula (III) is selected from cetyl palmitate, myristyl myristate, myristyl myristate and behenyl behenate.

8. The method according to claim 6, wherein at least one compound of general formula (III) is selected from cetyl palmitate, myristyl myristate, myristyl myristate and behenyl behenate.

9. The method according to any one of claims 1 to 3, wherein at least one compound of general formula (IV) is selected from lauryl alcohol, tridecanol, myristyl alcohol, pentadecanol, cetyl alcohol, palmityl alcohol, heptadecanol, stearyl alcohol or mixtures thereof.

10. The method according to claim 8, wherein at least one compound of formula (IV) is selected from lauryl alcohol, tridecanol, myristyl alcohol, pentadecanol, cetyl alcohol, palmityl alcohol, heptadecanol, stearyl alcohol or mixtures thereof.

11. The method according to any one of claims 1 to 3, wherein at least one compound of formula (V) is C 10 -C 18 Disodium alkyl sulfosuccinate.

12. The method according to claim 10, wherein at least one compound of formula (V) is C 10 -C 18 Disodium alkyl sulfosuccinate.

13. The method according to any one of claims 1 to 3, wherein at least one compound of general formula (VI) is selected from sodium lauroyl glutamate, sodium cocoyl glutamate, sodium myristoyl glutamate and sodium stearoyl glutamate.

14. The method according to claim 12, wherein the at least one compound of formula (VI) is selected from sodium lauroyl glutamate, sodium cocoyl glutamate, sodium myristoyl glutamate and sodium stearoyl glutamate.

15. The method according to any one of claims 1 to 3, wherein the liquid crystal lipid particles comprise cetearyl alcohol polyether, glyceryl stearate, cetyl palmitate, cetyl alcohol and stearyl alcohol.

16. The method of claim 14, wherein the liquid crystal lipid particles comprise cetearyl alcohol polyether, glyceryl stearate, cetyl palmitate, cetyl alcohol, and stearyl alcohol.

17. Use of at least one liquid crystal lipid particle for reducing the adhesion of dust to the skin, wherein the liquid crystal lipid particle comprises a compound represented by general formula (I) to (VI), including, At least one compound of formula (I) wherein m is an integer in the range of ≥10 to ≤24 and n is an integer in the range of ≥1 to ≤25, At least one compound of formula (II) wherein a is an integer in the range of ≥10 to ≤24, At least one compound of formula (III) wherein x is an integer in the range of ≥10 to ≤24 and y is an integer in the range of ≥10 to ≤25, At least one compound of formula (IV) Where p is an integer in the range of ≥10 to ≤16, At least one compound of formula (V) wherein A and B are each independently a hydrogen atom or an alkali metal or an alkaline earth metal, and R is a linear or branched, saturated or unsaturated C 10 -C 20 Aliphatic groups, and At least one compound of formula (VI) wherein r is an integer in the range of ≥9 to ≤18, and M is a hydrogen atom, an alkali metal or an alkaline earth metal, The liquid crystal lipid particles have a zeta potential greater than 20 mV.

18. The method according to claim 17, wherein the liquid crystal lipid particles have a lamellar structure with orthogonal transverse stacking.

19. The use according to claim 17, wherein the liquid crystal lipid particles have an average particle size of ≥20 nm to ≤300 nm as measured by dynamic light scattering using a Malvern DLS ZS90.

20. The use according to any one of claims 17 to 19, wherein at least one compound of general formula (I) is selected from cetearyl alcohol polyether, polyoxyethylene stearyl ether and polyoxyethylene cetyl ether.

21. The use according to any one of claims 17 to 19, wherein at least one compound of general formula (II) is selected from glyceryl stearate, glyceryl laurate and glyceryl palmitate.

22. The use according to claim 20, wherein at least one compound of general formula (II) is selected from glyceryl stearate, glyceryl laurate and glyceryl palmitate.

23. Use according to any one of claims 17 to 19, wherein at least one compound of general formula (III) is selected from cetyl palmitate, myristyl myristate, myristyl myristate and behenyl behenate.

24. The use according to claim 22, wherein at least one compound of general formula (III) is selected from cetyl palmitate, myristyl myristate, myristyl myristate and behenyl behenate.

25. The use according to any one of claims 17 to 19, wherein at least one compound of general formula (IV) is selected from lauryl alcohol, tridecanol, myristyl alcohol, pentadecanol, cetyl alcohol, palmityl alcohol, heptadecanol, stearyl alcohol or mixtures thereof.

26. The use according to claim 24, wherein at least one compound of general formula (IV) is selected from lauryl alcohol, tridecanol, myristyl alcohol, pentadecanol, cetyl alcohol, palmityl alcohol, heptadecanol, stearyl alcohol or mixtures thereof.

27. The use according to any one of claims 17 to 19, wherein at least one compound of general formula (V) is C 10 -C 18 Disodium alkyl sulfosuccinate.

28. The use according to claim 26, wherein at least one compound of formula (V) is C 10 -C 18 Disodium alkyl sulfosuccinate.

29. The use according to any one of claims 17 to 19, wherein at least one compound of general formula (VI) is selected from sodium lauroyl glutamate, sodium cocoyl glutamate, sodium myristoyl glutamate and sodium stearoyl glutamate.

30. The use according to claim 28, wherein at least one compound of formula (VI) is selected from sodium lauroyl glutamate, sodium cocoyl glutamate, sodium myristoyl glutamate and sodium stearoyl glutamate.

31. The use according to any one of claims 17 to 19, wherein the liquid crystal lipid particles comprise cetearyl alcohol polyether, glyceryl stearate, cetyl palmitate, cetyl alcohol and stearyl alcohol.

32. The use according to any one of claims 17 to 19, wherein the liquid crystal lipid particles comprise cetearyl alcohol polyether, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol and stearyl alcohol.

33. The use according to any one of claims 17 to 19, wherein the liquid crystal lipid particles include cetearyl alcohol polyether, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol, stearyl alcohol and selected from C 10 -C 18 Compound of disodium alkyl sulfosuccinate and sodium stearoyl glutamate.

34. according to the use described in any one of claims 17 to 19, wherein the liquid crystal lipid particles include ceteareth-20, ceteareth-12, glyceryl stearate, cetyl palmitate, myristyl myristate, cetyl alcohol, stearyl alcohol and selected from C 16 -C 18 Compound of disodium alkyl sulfosuccinate and sodium stearoyl glutamate.

35. A topical composition comprising, At least one liquid crystal particle according to any one of claims 1 to 34, at least one thickener, and water.

36. The topical composition of claim 35, wherein the at least one thickener is selected from the group consisting of xanthan gum, succinoglycans, gelatin, pectin, alginates, starches, guar gum, acrylates, acrylate copolymers, carbomers, and associative thickeners.

37. The topical composition of claim 35, wherein the at least one liquid crystal lipid particle is present in an amount of ≥ 1 wt% to ≤ 30 wt%, based on the total weight of the topical composition.

38. The topical composition of claim 36, wherein the at least one liquid crystal lipid particle is present in an amount of ≥ 1 wt% to ≤ 30 wt%, based on the total weight of the topical composition.

39. The topical composition according to any one of claims 35 to 38, wherein the at least one thickener is present in an amount of ≥ 0.1 wt. % to ≤ 5 wt. %, based on the total weight of the topical composition.

40. The topical composition of any one of claims 35 to 38, wherein water is present in an amount of ≥ 5 wt% to ≤ 80 wt%, based on the total weight of the topical composition.

41. The topical composition of any one of claims 35 to 38, further comprising at least one adjuvant selected from anti-wrinkle actives, anti-acne actives, emulsifiers, antioxidants, emollients, self-tanning actives, skin lightening agents, sunscreens, moisturizers, abrasives, absorbents, fragrances, buffers, sunscreens, colorants, preservatives, fillers, and pH adjusters.

42. The topical composition of any one of claims 35 to 38, wherein the topical composition is a skin care composition.

43. A topical composition according to any one of claims 35 to 38, wherein the topical composition is in the form of a cream, foam, lotion, gel, paste or ointment.

44. A method of reducing the adhesion of dust to the skin comprising applying to the skin a topical composition according to any one of claims 35 to 43.

Images